Literature DB >> 17451686

Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy.

Patrick W Reed1, Andrea M Corse, Neil C Porter, Kevin M Flanigan, Robert J Bloch.   

Abstract

To identify proteins expressed abnormally in facioscapulohumeral muscular dystrophy (FSHD), we extracted soluble proteins from deltoid muscle biopsies from unaffected control and FSHD patients and analyzed them using two-dimensional electrophoresis, mass spectrometry and immunoblotting. Muscles from patients with FSHD showed large increases over controls in a single soluble, 34 kDa protein (pI=5.08) identified by mass spectrometry and immunoblotting as mu-crystallin (CRYM). Soluble fractions of biopsies of several other myopathies and muscular dystrophies showed no appreciable increases in mu-crystallin. Mu-crystallin has thyroid hormone and NADPH binding activity and so may influence differentiation and oxidative stress responses, reported to be altered in FSHD. It is also linked to retinal and inner ear defects, common in FSHD, suggesting that its up-regulation may play a specific and important role in pathogenesis of FSHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451686     DOI: 10.1016/j.expneurol.2007.03.009

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  21 in total

1.  Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level.

Authors:  Rinse Klooster; Kirsten Straasheijm; Bharati Shah; Janet Sowden; Rune Frants; Charles Thornton; Rabi Tawil; Silvère van der Maarel
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

Review 2.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

3.  RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1).

Authors:  Lindsay M Wallace; Sara E Garwick-Coppens; Rossella Tupler; Scott Q Harper
Journal:  Mol Ther       Date:  2011-07-05       Impact factor: 11.454

4.  Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD.

Authors:  Yvonne D Krom; Julie Dumonceaux; Kamel Mamchaoui; Bianca den Hamer; Virginie Mariot; Elisa Negroni; Linda N Geng; Nicolas Martin; Rabi Tawil; Stephen J Tapscott; Baziel G M van Engelen; Vincent Mouly; Gillian S Butler-Browne; Silvère M van der Maarel
Journal:  Am J Pathol       Date:  2012-08-04       Impact factor: 4.307

Review 5.  Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?

Authors:  Mark Richards; Frédérique Coppée; Nick Thomas; Alexandra Belayew; Meena Upadhyaya
Journal:  Hum Genet       Date:  2011-10-09       Impact factor: 4.132

6.  DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.

Authors:  Lindsay M Wallace; Sara E Garwick; Wenyan Mei; Alexandra Belayew; Frederique Coppee; Katherine J Ladner; Denis Guttridge; Jing Yang; Scott Q Harper
Journal:  Ann Neurol       Date:  2010-12-08       Impact factor: 10.422

Review 7.  Zeta-crystallin: a moonlighting player in cancer.

Authors:  Matteo Lulli; Daniele Nencioni; Laura Papucci; Nicola Schiavone
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

8.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

Review 9.  Lysine metabolism in mammalian brain: an update on the importance of recent discoveries.

Authors:  André Hallen; Joanne F Jamie; Arthur J L Cooper
Journal:  Amino Acids       Date:  2013-09-17       Impact factor: 3.520

Review 10.  Imine reductases: a comparison of glutamate dehydrogenase to ketimine reductases in the brain.

Authors:  André Hallen; Joanne F Jamie; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2013-01-12       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.